BIOC Biocept

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.

Company profile

BIOC stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


31 Mar 21
13 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Biocept earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
20 Oct 20 Riccitelli Samuel D Employee Stock Option Common Stock Grant Aquire A No No 4.63 10,000 46.3K 10,000
1 Oct 20 Michael W. Nall Employee Stock Option Common Stock Grant Aquire A No No 4.5 241,500 1.09M 241,500
1 Oct 20 Michael J Terry Employee Stock Option Common Stock Grant Aquire A No No 4.5 48,300 217.35K 48,300
1 Oct 20 Timothy Kennedy Employee Stock Option Common Stock Grant Aquire A No No 4.5 138,000 621K 138,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

9.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 27 20 +35.0%
Opened positions 11 9 +22.2%
Closed positions 4 10 -60.0%
Increased positions 4 0 NEW
Reduced positions 5 11 -54.5%
13F shares
Current Prev Q Change
Total value 5.69M 4.83M +17.8%
Total shares 1.28M 1.1M +17.0%
Total puts 0 0
Total calls 30.3K 0 NEW
Total put/call ratio
Largest owners
Shares Value Change
Vanguard 667.24K $2.96M +1.9%
BLK Blackrock 191.63K $851K 0.0%
Driehaus Capital Management 111.11K $493K NEW
Geode Capital Management 86.54K $384K 0.0%
MS Morgan Stanley 48.45K $215K +48353.0%
Sabby Management 31.58K $140K NEW
Occudo Quantitative Strategies 31.13K $138K NEW
NTRS Northern Trust 26.46K $117K -4.4%
MNGPF Man 16.6K $74K NEW
BK Bank Of New York Mellon 16.24K $72K NEW
Largest transactions
Shares Bought/sold Change
Driehaus Capital Management 111.11K +111.11K NEW
Hussman Strategic Advisors 3.5K -80K -95.8%
MS Morgan Stanley 48.45K +48.35K +48353.0%
Sabby Management 31.58K +31.58K NEW
Occudo Quantitative Strategies 31.13K +31.13K NEW
MNGPF Man 16.6K +16.6K NEW
BK Bank Of New York Mellon 16.24K +16.24K NEW
VIRT Virtu Financial 14.65K +14.65K NEW
Vanguard 667.24K +12.64K +1.9%
Renaissance Technologies 0 -10.87K EXIT

Financial report summary

  • We are an early stage molecular oncology diagnostics company with a history of net losses; we expect to incur net losses in the future, and we may never achieve sustained profitability.
  • We need to raise additional capital to continue as a going concern.
  • If we are unable to increase sales of our current products, assays and services or successfully develop and commercialize other products, assays and services, our revenues will be insufficient for us to achieve profitability.
  • If we are unable to execute our sales and marketing strategy for our products and diagnostic assays and are unable to gain acceptance in the market, we may be unable to generate sufficient revenue to sustain our business.
  • If we cannot develop products, assays and services to keep pace with rapid advances in technology, medicine and science, our operating results and competitive position could be harmed.
  • If our current products, assays and services and our planned future products, assays and services do not continue to perform as expected, our operating results, reputation and business will suffer.
  • If our sole laboratory facility becomes damaged or inoperable, or we are required to vacate the facility, our ability to sell and provide our products and diagnostic assays and pursue our research and development efforts may be jeopardized.
  • Our business is subject to risks arising from epidemic diseases, such as the COVID-19 pandemic.
  • The successful development of a vaccine for COVID-19 may harm our RT-PCR COVID-19 testing business.
  • If we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenues or achieve and sustain profitability.
  • We expect to continue to incur significant expenses to develop and market products and diagnostic assays, which could make it difficult for us to achieve and sustain profitability.
  • Clinical utility studies are important in demonstrating to both customers and payers an assay’s clinical relevance and value. If we are unable to identify collaborators willing to work with us to conduct clinical utility studies, or the results of those studies do not demonstrate that an assay provides clinically meaningful information and value, commercial adoption of such assay may be slow, which would negatively impact our business.
  • The loss of key members of our executive management team could adversely affect our business.
  • There is a scarcity of experienced professionals in our industry. If we are not able to retain and recruit personnel with the requisite technical skills, we may be unable to successfully execute our business strategy.
  • Our failure to continue to attract, hire and retain a sufficient number of qualified sales professionals would hamper our ability to increase demand for our products and diagnostic assays, to expand geographically and to successfully commercialize any other products or assays we may develop.
  • Our dependence on commercialization partners for sales of products, assays and services could limit our success in realizing revenue growth.
  • We depend on third parties for the supply of blood samples and other biological materials that we use in our research and development efforts. If the costs of such samples and materials increase or our third-party suppliers terminate their relationship with us, our business may be materially harmed.
  • We currently rely on third-party suppliers for our BCTs, shipping kits, and critical materials needed to perform our current assays, as well as our planned future products, assays and services, and any problems experienced by them could result in a delay or interruption of their supply to us.
  • If we were sued for product liability or professional liability, we could face substantial liabilities that exceed our resources.
  • If we use biological and hazardous materials in a manner that causes injury, we could be liable for damages.
  • We may acquire other businesses or form joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense.
  • If we cannot support demand for our current products, assays and services, as well as our planned future products, assays and services, including successfully managing the evolution of our laboratory service, our business could suffer.
  • Billing for our diagnostic assays is complex, and we must dedicate substantial time and resources to the billing process to be paid.
  • We rely on third-party billing provider software, and an in-house billing function, to transmit claims to payers, and any delay in transmitting claims could have an adverse effect on our revenue.
  • We may encounter manufacturing problems or delays that could result in lost revenue.
  • International expansion of our business would expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.
  • General economic or business conditions may have a negative impact on our business.
  • Intrusions into our computer systems could result in compromise of confidential information.
  • We depend on our information technology and telecommunications systems, and any failure of these systems could harm our business.
  • Healthcare policy changes, including recently enacted legislation reforming the U.S. health care system, may have a material adverse effect on our financial condition, results of operations and cash flows.
  • Our commercial success could be compromised if hospitals or other clients do not pay our invoices or if third-party payers, including managed care organizations and Medicare, do not provide coverage and reimbursement, breach, rescind or modify their contracts or reimbursement policies or delay payments for our current assays and our planned future assays.
  • We expect to depend on Medicare and a limited number of private payers for a significant portion of our revenues and if these or other payers stop providing reimbursement or decrease the amount of reimbursement for our current assays and our planned future assays, our revenues could decline.
  • Because of certain Medicare billing policies, we may not receive complete reimbursement for assays provided to Medicare patients. Medicare reimbursement revenues are an important component of our business model, and private payers sometimes look to Medicare determinations when making their own payment determinations; therefore, incomplete or inadequate reimbursement from Medicare would negatively affect our business.
  • We may not receive breakthrough device designation by the FDA for our Target-Selector CSF Assay, and even if we do, such designation may not lead to a faster development, regulatory review or clearance process, and it may not increase the likelihood that the assay will receive marketing authorization from the FDA.
  • Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.
  • If the FDA were to begin requiring approval or clearance of our current products or assays and our planned future products or assays, we could incur substantial costs and time delays associated with meeting requirements for pre-market clearance or approval or we could experience decreased demand for, or reimbursement of, our assays.
  • If we were required to conduct additional clinical studies or trials before continuing to offer assays that we have developed or may develop as LDTs, those studies or trials could lead to delays or failure to obtain necessary regulatory approval, which could cause significant delays in commercializing any future products and harm our ability to achieve sustained profitability.
  • We are subject to federal and state healthcare fraud and abuse laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.
  • We are required to comply with laws governing the transmission, security and privacy of health information that require significant compliance costs, and any failure to comply with these laws could result in material criminal and civil penalties.
  • Clinical research is heavily regulated and failure to comply with human subject protection regulations may disrupt our research program leading to significant expense, regulatory enforcement, private lawsuits and reputational damage.
  • Violation of a state’s prohibition on the corporate practice of medicine could result in a material adverse effect on our business.
  • If we are unable to obtain and maintain effective patent rights for our products or services, we may not be able to compete effectively in our markets.
  • Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.
  • If we are unable to maintain effective proprietary rights for our products or services, we may not be able to compete effectively in our markets.
  • Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.
  • We may not be successful in obtaining or maintaining necessary rights to our products or services through acquisitions and in-licenses.
  • Although we are not currently involved in any litigation, we may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.
  • We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • We may be subject to claims challenging the inventorship of our patents and other intellectual property.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Our collaborators may assert ownership or commercial rights to inventions we develop from our use of the biological materials which they provide to us, or otherwise arising from the collaboration.
  • The price of our common stock may be volatile.
  • Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a de-listing of our common stock.
  • Our quarterly operating results may fluctuate significantly.
  • Future sales of our common stock or other securities, or the perception that future sales may occur, may cause the market price of our common stock to decline, even if our business is doing well.
  • If we are unable to favorably assess the effectiveness of our internal control over financial reporting, investors may lose confidence in our financial reporting and our stock price could be materially adversely affected.
  • Anti-takeover provisions of our certificate of incorporation, our bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove the current members of our board and management.
  • Because we do not expect to pay cash dividends for the foreseeable future, you must rely on appreciation of our common stock price for any return on your investment. Even if we change that policy, we may be restricted from paying dividends on our common stock.
  • Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.
  • Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.
  • Our ability to use our estimated net operating loss carryforwards and certain other tax attributes may be limited.
  • We could be subject to securities class action litigation.
  • We have incurred and will continue to incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.
  • If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline.
Management Discussion
  • Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
  • We are an early-stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor nucleic acid including circulating tumor DNA, or ctDNA, and circulating tumor RNA, or ctRNA, assays using a standard blood sample, or “liquid biopsy.” Effective January 2020, we also adapted and validated this technology for commercial use in cerebrospinal fluid, or CSF, to identify tumor cells that have metastasized to the central nervous system, or CNS, in patients with advanced lung cancer or breast cancer.
  • In June of 2020, to respond to a national public health emergency precipitated by the COVID-19 pandemic, we introduced molecular testing for SARS-CoV2, the virus responsible for COVID-19, using a United States Food and Drug Administration, or FDA, Emergency Use Authorization, or EUA, based “RT-PCR” method developed by Thermo-Fisher.
Content analysis
H.S. junior Avg
New words: abatement, adequacy, anesthesiologist, array, aspect, Atlanta, attained, Biden, Biofluidica, biotech, blinded, Brazil, carrier, carryback, clerical, combating, Conformit, counsel, COVID, CSI, CT, ctRNA, cytology, debilitating, EKRA, Emory, equivocal, etcetera, EUA, expedite, expedited, extremely, faster, FFPE, filer, foot, headquartered, heath, home, house, inconvenient, Inivata, Invitae, irreversibly, jury, Kettering, lumbar, Lurie, magnitude, matter, MCCP, Med, Mesa, metastasized, military, mission, Monica, MultiPlan, Northwestern, novo, nurse, nursing, online, Penn, pharma, piece, pool, preapproved, presidential, primer, pronouncement, prorated, puncture, QNS, qPCR, qualification, quantity, queue, radiologic, ratio, RavGen, reconsider, repricing, residual, resume, Rim, risky, RNA, Road, Santa, Scientist, shortage, Sloan, Southern, speculative, Stanford, summarized, supposed, sweeping, tap, transposed, trend, TRICARE, TriWest, trouble, unbilled, unnecessary, unqualified, urgent, usability, vaccinated, vaccine, verified, vet, week, West, withdrawn, workforce
Removed: Adnagen, Agena, Agendia, Alere, amortizing, Apocell, Atossa, BCT, bioMerieux, cerebral, challenged, circumvented, Clearbridge, Codification, consecutive, converted, Cynvenio, eliminated, entry, essential, expiring, float, Fluxion, GlaxoSmithKline, Grail, hedge, hedged, hedging, infringed, interpret, Israel, Kennedy, line, loan, locally, lymphoma, mainstream, maturity, Michael, microarray, misappropriated, Nall, nonfinancial, optional, Oregon, Oxford, passage, personalization, Pfizer, reclassification, recurring, relocating, resection, retained, ScreenCell, Secretary, simplifying, stranded, Tafinlar, TCTM, Terry, Timothy, Turkey, Unaudited, Uruguay, vast, warehouse, Xalkori, Zelboraf